Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
Public ClinicalTrials.gov record NCT02776072. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of the study is to evaluate the real-world clinical effectiveness, as measured by the proportion of participants relapsed at 12 months, in participants treated with dimethyl fumarate (DMF). Secondary objectives of the study are: To evaluate the real-world clinical effectiveness, as measured by the proportion of participants relapsed at 12 months, in participants treated with DMF, glatiramer acetate (GA), teriflunomide, or fingolimod both in the overall participant cohort and in a subset of participants who were naïve to disease-modifying therapy (DMT) and were diagnosed with multiple sclerosis (MS) within 3 years of starting the index therapy; To compare relapse activity, defined as annualized relapse rate (ARR), among participants treated with DMF, GA, teriflunomide, or fingolimod; To compare MS-related hospitalizations among participants treated with DMF, GA, teriflunomide, or fingolimod; To compare intravenous corticosteroid use among participants treated with DMF, GA, teriflunomide, or fingolimod.
Study identification
- NCT ID
- NCT02776072
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 2,978 participants
Conditions and interventions
Conditions
Interventions
Not listed
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 2016 (Type not available)
- Primary completion
- Dec 2016 (Actual)
- Completion
- Dec 2016 (Actual)
- Last update posted
- Mar 23, 2017
2016
United States locations
- U.S. sites
- 38
- U.S. states
- 20
- U.S. cities
- 36
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Homewood | Alabama | 35209 | — |
| Research Site | Gilbert | Arizona | 85234 | — |
| Research Site | Hanford | California | 93230 | — |
| Research Site | Modesto | California | 95355 | — |
| Research Site | Santa Ana | California | 92704 | — |
| Research Site | Aurora | Colorado | 80045 | — |
| Research Site | Danbury | Connecticut | 06810 | — |
| Research Site | Hartford | Connecticut | 6112 | — |
| Research Site | Jacksonville | Florida | 32256 | — |
| Research Site | Port Orange | Florida | 32127 | — |
| Research Site | Savannah | Georgia | 31406 | — |
| Research Site | Avon | Indiana | 46123 | — |
| Research Site | Franklin | Indiana | 46131 | — |
| Research Site | Muncie | Indiana | 47304 | — |
| Research Site | Overland Park | Kansas | 66212 | — |
| Research Site | Boston | Massachusetts | 02135 | — |
| Research Site | Boston | Massachusetts | 02215 | — |
| Research Site | Wellesley | Massachusetts | 02481 | — |
| Research Site | Golden Valley | Minnesota | 55422 | — |
| Research Site | Amherst | New York | 14226 | — |
| Research Site | New Hyde Park | New York | 11042 | — |
| Research Site | New York | New York | 10019 | — |
| Research Site | Patchogue | New York | 11772 | — |
| Research Site | Raleigh | North Carolina | 27607-6010 | — |
| Research Site | Cleveland | Ohio | 44195 | — |
| Research Site | Columbus | Ohio | 43210 | — |
| Research Site | Columbus | Ohio | 43221 | — |
| Research Site | Medford | Oregon | 97504 | — |
| Research Site | Portland | Oregon | 97225 | — |
| Research Site | Philadelphia | Pennsylvania | 19107 | — |
| Research Site | Pittsburgh | Pennsylvania | 15212 | — |
| Research Site | Dallas | Texas | 75246 | — |
| Research Site | Houston | Texas | 77018 | — |
| Research Site | Mansfield | Texas | 76063 | — |
| Research Site | Round Rock | Texas | 78681 | — |
| Research Site | Salt Lake City | Utah | 84103 | — |
| Research Site | Norfolk | Virginia | 23502 | — |
| Research Site | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 83 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02776072, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 23, 2017 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02776072 live on ClinicalTrials.gov.